Table 30Total cost differences in annual medical care among persons filling prescriptions for OAB drug treatment

Author YearGroupsCost Outcomes
Type of prescription filledAverage PPPY Total Costs before treatment ($), Unadjusted, Mean $ cost ± SDAverage PPPY Total Costs after treatment initiation ($), Unadjusted, Mean $ ± SDStatistical significanceReference standard
Nitz et al.178 2005G1: Oxybutynin IRG1: 4956 ± 14396G1: 7083 ± 39420G1/G3:NR
G2: Oxybutynin ERG2: 4146 ± 8695G2: 5980 ± 13263P <0.05
G3: Tolterodine ERG3: 3349 ± 6715G3: 5074 ± 11007
G1/G2: NS
G2/G3: NS
Hall et al.176 2001G1: TolterodineG1: 5004G1: 7020NRNR
G2: OxybutyninG2: 5688G2: 7116
G3: Flavoxate or other OAB medicationG3: 5352G3: 7380
G4: No drug treatment for OABG4: 2928G4: 5040
Varadharajan et al.175 2005 (women only)G1: Tolterodine ER*NRG1: 8303 ± 18802G1vG2:2004 US dollars
G2: Oxybutynin ERG2: 8862 ± 18684p=0.0109
G3: Tolterodine ER*G3: 9975 ± 42860G3vG4:
G4: Oxybutynin IRG4: 10521 ± 22602p=0.3612

PPPY = per person per year;

*

Separate groups matched according to G2 and G4

From: Chapter 3, Results

Cover of Treatment of Overactive Bladder in Women
Treatment of Overactive Bladder in Women.
Evidence Reports/Technology Assessments, No. 187.
Hartmann KE, McPheeters ML, Biller DH, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.